Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EPS (Weighted Average and Diluted) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$4.74 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 70.08% to -$4.74 in Q3 2025 year-over-year; TTM through Sep 2025 was $10.53, a 163.82% increase, with the full-year FY2024 number at -$0.75, up 17.58% from a year prior.
  • EPS (Weighted Average and Diluted) was -$4.74 for Q3 2025 at bioAffinity Technologies, down from -$0.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $15.47 in Q4 2024 to a low of -$15.84 in Q3 2024.
  • A 4-year average of -$0.58 and a median of -$0.2 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 5829.63% in 2024; the steepest drop was 5992.31% in 2024.
  • bioAffinity Technologies' EPS (Weighted Average and Diluted) stood at -$0.37 in 2022, then rose by 27.46% to -$0.27 in 2023, then surged by 5829.63% to $15.47 in 2024, then crashed by 130.64% to -$4.74 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EPS (Weighted Average and Diluted) are -$4.74 (Q3 2025), -$0.04 (Q2 2025), and -$0.16 (Q1 2025).